Exelixis (EXEL) Set to Release Quarterly Earnings on Thursday

Exelixis (NASDAQ:EXEL) is expected to release its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to post earnings of $0.8790 per share and revenue of $646.52 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, October 29, 2026 at 5:00 PM ET.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Wednesday, August 5th. The biotechnology company reported $0.91 EPS for the quarter, topping analysts’ consensus estimates of $0.85 by $0.06. The firm had revenue of $628.69 million for the quarter, compared to analysts’ expectations of $636.40 million. Exelixis had a return on equity of 42.17% and a net margin of 35.33%. The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.75 EPS. On average, analysts expect Exelixis to post $3.19 EPS for the current fiscal year and $3.71 EPS for the next fiscal year.

Exelixis Price Performance

EXEL opened at $64.58 on Thursday. The stock has a 50-day moving average price of $57.63 and a 200-day moving average price of $53.38. The firm has a market cap of $16.00 billion, a PE ratio of 20.31, a P/E/G ratio of 1.81 and a beta of 0.47. Exelixis has a 1 year low of $35.44 and a 1 year high of $64.78.

Insider Activity

In related news, Director Mary Beckerle sold 9,812 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $53.66, for a total transaction of $526,511.92. Following the sale, the director directly owned 16,079 shares of the company’s stock, valued at $862,799.14. This trade represents a 37.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.60% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Citigroup restated a “market outperform” rating on shares of Exelixis in a research note on Monday. Wells Fargo & Company lifted their target price on shares of Exelixis from $40.00 to $49.00 and gave the stock an “equal weight” rating in a report on Monday, July 13th. Zacks Research upgraded shares of Exelixis from a “strong sell” rating to a “hold” rating in a research note on Tuesday, September 1st. Leerink Partners cut shares of Exelixis from an “outperform” rating to a “market perform” rating and set a $52.00 price target on the stock. in a report on Thursday, August 6th. Finally, UBS Group set a $55.00 price target on shares of Exelixis in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $51.50.

About Exelixis

Exelixis, Inc is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for cancer and other serious diseases. The company’s research programs center primarily on targeted therapies, including treatments designed to inhibit signaling pathways involved in tumor growth and progression.

Exelixis’ lead product is CABOMETYX (cabozantinib), an oral medicine approved in the United States for certain patients with renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer.